news

European Commission approves Rytelo for LR- MDS-related anaemia

4
SHARES

The European marketing authorisation offers a new treatment option for patients with transfusion-dependent anaemia in lower-risk myelodysplastic syndromes (LR-MDS), who are unresponsive to erythropoiesis-stimulating agents.

Rytelo LR- MDS-related anaemia

The European Commission (EC) has granted the first telomerase inhibitor approval in the EU for adults with transfusion-dependent anaemia due to very low, low, or intermediate-risk myelodysplastic syndromes (LR-MDS). The marketing authorisation for Rytelo ® (imetelstat) applies to those without an isolated deletion 5q abnormality who are ineligible for or unresponsive to erythropoiesis-stimulating agents (ESAs). It marks a significant milestone for patients with LR- MDS-related anaemia who have limited treatment options beyond ESAs.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

This decision for Rytelo is applicable across all 27 EU Member States, as well as Iceland, Norway, and Liechtenstein. This new approval by the EC follows the US FDA’s approval in June 2024.

Evidence from clinical trials for Rytelo in LR- MDS-related anaemia

The marketing authorisation is supported by data from the IMerge Phase III trial, which demonstrated that Rytelo significantly reduced red blood cell transfusion dependency in LR-MDS patients. The study found that a substantial proportion of patients achieved prolonged transfusion independence, with some maintaining responses for over a year. The drug, administered intravenously every four weeks, inhibits telomerase activity, a key factor in malignant stem cell proliferation in bone marrow.

As the first and only treatment of its kind, Rytelo represents an important new [treatment] option”

The therapy’s overall benefit-risk profile was deemed favourable for patients with limited alternatives after ESA failure. Therefore, Rytelo’s approval marks a significant advancement for patients seeking long-term transfusion independence.

“As the first and only treatment of its kind, Rytelo represents an important new option – significantly reducing the need for red blood cell transfusions for people living with LR-MDS who are battling debilitating symptoms like anaemia and fatigue,” Dr Joseph Eid, Executive Vice President of Research and Development at Geron stated.

“The long-term and durable responses observed in the Phase III IMerge study reinforce the practice-changing potential of telomerase inhibition as a clinically meaningful and differentiated option for the treatment of lower-risk MDS,” Dr Uwe Platzbecker, co-lead author of the Phase III trial added.

Market access and future plans

Geron plans to launch Rytelo (imetelstat) in select European countries by 2026, pending national reimbursement approvals. Additionally, the EMA has recommended maintaining Rytelo’s orphan drug designation, potentially securing ten years of market exclusivity.

Share via
Share via